Navigation Links
FDA Approves Labeling Change for Non-Drowsy CLARITIN(R)
Date:1/22/2008

Label Highlights CLARITIN Effectively Treats Indoor and Outdoor Allergies

KENILWORTH, N.J., Jan. 22 /PRNewswire-FirstCall/ -- Schering-Plough (NYSE: SGP) today announced that the U.S. Food and Drug Administration has approved additional labeling for CLARITIN(R) (loratadine), which clearly tells consumers that the non-drowsy over-the-counter medication relieves allergy symptoms caused by both indoor (also called perennial or year-round) and outdoor (also called seasonal) allergies.

"Schering-Plough is pleased that the FDA has approved the change to the CLARITIN label to help us to communicate to consumers that CLARITIN works hard to relieve both indoor and outdoor allergies," said John E. O'Mullane, BSc, PhD, Group Vice-President, Research and Development, Schering-Plough Consumer Health Care.

Common indoor allergens include mold, dust mites, and pet dander, while common outdoor allergens include grass, tree, and ragweed pollen. Though they stem from different sources, indoor and outdoor allergies have the same pathophysiology, meaning they affect the body in the same way. Symptoms of both types of allergies include runny nose; sneezing; itchy, watery eyes; and itching of the nose or throat.

"People often associate allergies with outdoor triggers like pollen and grass, but many people's allergies are actually caused by things found in their home, office, or school," said Marjorie Slankard, M.D., allergist and clinical professor of medicine at the Columbia University College of Physicians and Surgeons. "When choosing an allergy medication, it's important to recognize that not all treatments are the same. Many patients and providers prefer a non-drowsy antihistamine, such as CLARITIN, because of its proven record in relieving symptoms of indoor and outdoor allergies." CLARITIN is the only brand proven to keep allergy sufferers as alert and focused as someone without allergies.* Allergy sufferers who are unsure about which treatment option is right for them should talk to their doctors.

CLARITIN is approved as effective against indoor (perennial) allergies in 110 countries worldwide.

*Only brand clinically tested.

About CLARITIN

All CLARITIN brand products are available without a prescription, including: CLARITIN Tablets, a once-daily full prescription strength, non- drowsy formulation; CLARITIN RediTabs(R) Tablets, a novel once-daily formulation in a quickly dissolving tablet for ages 6 and older; CLARITIN-D(R) 24-hour and 12-hour Extended Release Tablets, with the decongestant pseudoephedrine now located behind the counter; CHILDREN'S CLARITIN(R) Syrup, a liquid formulation for children ages 2 and older in grape and fruit flavors; CHILDREN'S CLARITIN(R) Grape Chewables, a chewable tablet for children ages 2 and older; and CLARITIN Hives Relief(TM) tablets.

CLARITIN is the No. 1 physician-recommended and pediatrician-recommended over-the-counter antihistamine brand for allergic rhinitis. The CLARITIN Rx- to-OTC switch in 2002 was the largest switch ever-and the first and only for a non-sedating antihistamine. For more information on allergies and treatment, visit http://www.CLARITIN.com.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... , ... In the United States, single-family home owners pay ... York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 a ... rates, which contributes to the relatively lower cost of living in places like ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
Breaking Medicine Technology: